Kyle Dempsey
Direktor/Vorstandsmitglied bei OPTINOSE, INC.
Vermögen: 6 089 $ am 30.04.2024
Aktive Positionen von Kyle Dempsey
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
OPTINOSE, INC. | Direktor/Vorstandsmitglied | 10.12.2021 | - |
Independent Dir/Board Member | 10.12.2021 | - | |
HLS THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 29.11.2022 | - |
Independent Dir/Board Member | 29.11.2022 | - | |
MVM Partners LLC | Private Equity Investor | 01.09.2017 | - |
GT Medical Technologies, Inc.
GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Kyle Dempsey
Ausbildung von Kyle Dempsey
Bowdoin College | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Harvard Business School | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 7 |
Kanada | 2 |
Operativ
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Private Equity Investor | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 4 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
OPTINOSE, INC. | Health Technology |
HLS THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
MVM Partners LLC | Finance |
GT Medical Technologies, Inc.
GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Health Technology |
- Börse
- Insiders
- Kyle Dempsey
- Erfahrung